Cancer trial enrollment after state-mandated reimbursement

Journal of the National Cancer Institute

Volumn 96, Issue 14, 2004, Pages 1063-1069

  Gross, Cary P ^a   Murthy, V ^a   Li, Y ^a   Kaluzny, A D ^b   Krumholz, H M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RESEARCH; CLINICAL TRIAL; COLORECTAL CANCER; GOVERNMENT; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH INSURANCE; HUMAN; LUNG CANCER; MEDICARE; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE PAYMENT; PROSTATE CANCER; RACE DIFFERENCE; REGRESSION ANALYSIS; REIMBURSEMENT; RETROSPECTIVE STUDY; SAMPLE SIZE; STATISTICAL ANALYSIS; BREAST TUMOR; COLORECTAL TUMOR; ECONOMICS; FEMALE; GOVERNMENT REGULATION; INCIDENCE; LEGAL ASPECT; LONGITUDINAL STUDY; LUNG TUMOR; MALE; MULTICENTER STUDY; NEOPLASM; POISSON DISTRIBUTION; PROSTATE TUMOR; STATISTICAL MODEL; UNITED STATES;

BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; COLORECTAL NEOPLASMS; FEMALE; GOVERNMENT REGULATION; HUMANS; INCIDENCE; LOGISTIC MODELS; LONGITUDINAL STUDIES; LUNG NEOPLASMS; MALE; MULTICENTER STUDIES; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASMS; PATIENT SELECTION; POISSON DISTRIBUTION; PROSTATIC NEOPLASMS; REIMBURSEMENT MECHANISMS; RETROSPECTIVE STUDIES; STATE GOVERNMENT; UNITED STATES;

EID: 3242681568     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh193     Document Type: Article

References (51)

1. National Cancer Institute. Report of the National Cancer Institute clinical trial program review group. Bethesda (MD): National Cancer Institute; 1997.
2. Friedman M, Cain D. National Cancer Institute sponsored cooperative clinical trials. Cancer 1990;65(10 Suppl):2376-82.
3. National Cancer Institute, Group BCPR. Charting the course: priorities for breast cancer research. Bethesda (MD): National Cancer Institute; 1999 Aug.
4. Sung NS, Crowley WF Jr, Genel M, Salber P, Sandy L, Sherwood LM, et al. Central challenges facing the national clinical research enterprise. JAMA 2003;289:1278-87.
5. Shavers-Hornaday V, Lynch C, Burmeister L, Torner J. Why are African-Americans under-represented in medical research studies? Impediments to participation. Ethn Health 1997;2:31-45.
6. Foley J, Moertel C. Improving accrual into cancer clinical trials. J Cancer Educ 1991;6:165-73.
7. Fleming R. Barriers to clinical trials. Part I: reimbursement problems. Cancer 1994;74:2662-5.
8. Fallowfield L, Ratcliffe D, Souhami R. Clinicians' attitudes to clinical trials of cancer therapy. Eur J Cancer 1997;33:2221-9.
9. Swanson D, Ward A. Recruiting minorities into clinical trials: toward a participant-friendly system. J Natl Cancer Inst 1995;87:1747-59.
10. National Cancer Institute, Advisors BoS. Report of the National Cancer Institute Clinical Trials Program Review Group. Bethesda (MD): National Cancer Insitute; 1997 Aug 26.
11. Hutchins L, Unger J, Crowley J, Coltman C, Albain K. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061-7.
12. Goodman C. Investigational exclusion, clinical trials, and cancer. NCCN Proc 1998;12:37-49.
13. Vogelzang N, Richards J. Third party reimbursement issues during a phase I trial of interleukin 2. J Natl Cancer Inst 1989;81:544-5.
14. NIH Clinical Trials: Various factors affect patient participation. Washington (DC): US General Accounting Office; 1999 Sept Report No.: GAO/HEHS-99-182. Available at: http://www.gao.gov/archive/1999/he99182.pdf. [Last accessed: June 4, 2004.]
15. Comis R, Aldige C, Stovall E, Krebs L, Risher P, Taylor H. A quantitative survey of public attitudes towards cancer clinical trials [2000]. Available at: http://www.asco.org/ac/1,1003,_12-002636-00_18-002-00_19-00100188,00.asp? AbstractID=100188&cat=&parent=&returnpid=. [Last accessed: June 7, 2004.]
16. Kolata G, Eichenwald. Group of insurers to pay for experimental cancer therapy. The New York Times 1999 Dec 16;Sect. C:1, C:9.
17. ECRI. Should I enter a clinical trial? American Association of Health Plans. Available at: http://www.ecri.org/Patient_Information/Patient_Reference_Guide/prg.pdf. [Last accessed: June 4, 2004.]
18. Kassirer J. Practicing medicine without a license - the new intrusions by Congress. N Engl J Med 1997;336:1747.
19. Rathore S, McGreevey J, Schulman K, Atkins D. Mandated coverage for cancer-screening services: whose guidelines do states follow? Am J Prev Med 2000;19:71-8.
20. Schauffler H. Politics trumps science: rethinking state-mandated benefits. Am J Prev Med 2000;19:136-7.
21. Jensen G. Mandated benefit laws and employer-sponsored health insurance: Health Insurance Association of America; 1999 Jan 6. Available at: http://www.hiaa.org. [Last accessed: June 7, 2004.]
22. Mathews M. Do we need mental health parity? Available at: http://www.ncpa.org/ba/ba297.html. [Last accessed: June 4, 2004.]
23. National Center for Policy Analysis. State mandated health insurance benefits. Available at: http://www.ncpa.org/w/w23.html. [Last accessed: June 4, 2004.]
24. American Cancer Society. Cancer facts and figures - 1999. Atlanta (GA): American Cancer Society; 1999.
25. Clinical Data Update System. Available at: http://ctep.cancer.gov/forms/CDUS_IG_3r2.pdf. [Last accessed: June 7, 2004.]
26. Greenlee R, Hill-Harmon M, Murray T, Thun M. Cancer Statistics 2001. CA Cancer J Clin 2001;51:15-36.
27. Greenlee R, Murray T, Bolden S, Wingo P. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
28. Landis S, Murray T, Bolden S, Wingo P. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31.
29. Landis S, Murray T, Bolden S, Wingo P. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
30. Parker S, Tong T, Bolden S, Wingo P. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
31. Parker S, Tong T, Bolden S, Wingo P. Cancer statistics, 1996. CA Cancer J Clin 1996;46:5-27.
32. Clinton W. Executive order from President Clinton to DHHS Secretary Shalala. Washington DC: Federal Register (June 12, 2000).
33. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003;289:454-65.
34. Gertz K, Zisson S. Clinical grants market decelerates. Centerwatch 2003; 10:4-5.
35. Wagner JL, Alberts SR, Sloan JA, Cha S, Killian J, O'Connell MJ, et al. Incremental costs of enrolling cancer patients in clinical trials: a population-based study. J Natl Cancer Inst 1999;91:847-53.
36. Goldman DP, Berry SH, McCabe MS, Kilgore ML, Potosky AL, Schoenbaum ML, et al. Incremental treatment costs in National Cancer Institute-sponsored clinical trials. JAMA 2003;289:2970-7.
37. Summit Series on Cancer Clinical Trials. http://www.cancersummit.org/summit_meetings/summit_I_summary.pdf. [Last accessed: June 7, 2004.]
38. Schneider L, Olin J, Lyness S, Chui H. Eligibility of Alzheimer's disease clinic patients for clinical trials. J Am Geriatr Soc 1997;45:923-8.
39. Licht R, Gouliaev G, Vestergaard P, Frydenberg M. Generalisability of results from randomised drug trials. Br J Psychiatry 1997;170:264-7.
40. Campbell EG, Weissman JS, Causino N, Blumenthal D. Market competition and patient-oriented research: the results of a national survey of medical school faculty. Acad Med 2001;76:1119-26.
41. Fleming I. Clinical trials for cancer patients: the community practicing physician's perspective. Cancer 1990;65:2388-90.
42. Kaluzny A, Warnecke R. Managing a health care alliance: improving community cancer care. San Francisco (CA): Jossey-Bass (Reprinted Beard Books, 2001); 1996.
43. Werner R, Alexander G, Fagerlin A, Ubel P. The "Hassle Factor": what motivates physicians to manipulate reimbursement rates? Arch Intern Med 2002;162:1134-9.
44. Freeman V, Rathore S, Weinfurt K, Schulman K, Sulmasy D. Lying for patients: physician deception of third-party payers. Arch Intern Med 1999; 159:2263-70.
45. Moran M. New Jersey insurers will pay for care in cancer clinical trials. American Medical News 2000(January 17):1-4. Available at: http://www.ama-assn.org/amednews/2000/01/17/hll20117.htm. [Last accessed: June 4, 2004.]
46. National Cancer Institute. Cancer clinical trials: broadening access for patients and physicians. Available at: http://cancer.gov/clinicaltrials/conducting/new-national-system/page4. [Last accessed: June 7, 2004.]
47. National Institutes of Health. Re-engineering the clinical research enterprise. Available at: http://nihroadmap.nih.gov/clinicalresearch/index.asp. [Last accessed: June 4, 2004.]
48. National Cancer Institute. Notice of limited competition exploratory/developmental grants: overcoming barriers to early phase clinical trials. Bethesda (MD): National Cancer Institute; 2002 May 21.
49. Bennett C, Adams J, Knox K, Kelahan A, Silver S, Bailes J. Clinical trials: are they a good buy? J Clin Oncol 2001;19:4330-9.
50. Dane P, Wright A. Effect of a legislative mandate on mammography use and coding practices in Maryland. Radiology 1996;198:657-60.
51. Walshe R, Rundall TG. Evidence-based management: from theory to practice in health care. The Milbank Quarterly 2001;79:429-57. Available at: http://www.milbank.org/790304.html. [Last accessed: June 4, 2004.]